Enanta (ENTA) Form 4: CFO gets 6,463 RSUs, 12,925 options

Enanta Pharmaceuticals (ENTA) reported an equity compensation grant to its Vice President, Finance, who is its principal financial officer.

Rhea-AI Filing Summary

Enanta Pharmaceuticals (ENTA) reported an equity compensation grant to its Vice President, Finance, who is its principal financial officer. On 11/25/2025, the officer received 6,463 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing direct beneficial ownership of common stock to 17,375 shares following the transaction. The RSUs vest 25% on December 1, 2026, then in substantially equal annual installments over the next three anniversaries.

The filing also reports a grant of a stock option for 12,925 shares of common stock at an exercise price of $13.66 per share, expiring on 11/25/2035. This option becomes exercisable in substantially equal quarterly installments over four years from the grant date of November 25, 2025, resulting in 12,925 derivative securities beneficially owned after the transaction, all held directly.

Insider Trade Summary

Grant/Award: 19,388 shares

Grant/Award 2 txns

Insider Trout Harry R. III

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	12,925	$0.00	$0.00
Grant/Award	Common Stock	6,463	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 12,925 contracts (Direct); Common Stock — 17,375 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter.
2. F2. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ENTA report in this Form 4?

Enanta Pharmaceuticals reported that its Vice President, Finance (principal financial officer) received 6,463 shares of common stock as a restricted stock unit grant and a stock option for 12,925 shares on 11/25/2025.

How many Enanta (ENTA) shares does the reporting person own after this transaction?

After the reported transaction, the officer beneficially owns 17,375 shares of Enanta common stock directly, plus 12,925 stock options as derivative securities.

What are the vesting terms of the Enanta (ENTA) RSU grant?

The 6,463 RSUs vest and settle as follows: 25% of the award on December 1, 2026, with the remaining units vesting in substantially equal annual installments over the next three anniversaries.

What are the terms of the Enanta (ENTA) stock option granted in this Form 4?

The stock option covers 12,925 shares of common stock at an exercise price of $13.66 per share, granted on 11/25/2025 and expiring on 11/25/2035.

How does the Enanta (ENTA) stock option vest for the reporting person?

The option becomes exercisable in substantially equal quarterly installments over four years from the grant date of November 25, 2025, subject to continued employment, with fractional shares cumulated.

Does each RSU in the Enanta (ENTA) grant equal one share of stock?

Yes. Each restricted stock unit represents the contingent right to receive, upon vesting, one share of Enanta common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trout Harry R. III

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		A(1)		6,463	A	$0	17,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	11/25/2025		A		12,925		(2)	11/25/2035	Common Stock	12,925	$0.00	12,925	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter.

2. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

Remarks:

Vice President, Finance (Principal Financial Officer)

	/s/ Matthew Kowalsky as attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.